GSK terminates antibiotic development after microbiological finding
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals says its partner GlaxoSmithKline is returning the rights to GSK2251052, a boron-based experimental antibiotic that had been in development to treat Gram-negative bacterial infections.